The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.Combinación que comprende un inhibidor de la quinasa Mps-1 y un inhibidor de la mitosis. Su uso en el tratamiento del cáncer, particularmente del cáncer de páncreas, del glioblastoma, del cáncer de ovario, del carcinoma de pulmón a células no pequeñas, del cáncer de mama y/o del cáncer gástrico.